Mesothelioma is a rare and aggressive cancer arising from mesothelial cells lining the pleura, peritoneum, or other serosal surfaces, most commonly linked to asbestos exposure. Prognosis is often poor because diagnosis frequently occurs at advanced stage.
A phase one trial of RSO-021 achieved disease control in 67% of relapsed mesothelioma patients. Other advances include daraxonrasib for NRAS-driven melanoma, an aneuploidy biomarker for PARP inhibitor response in childhood cancers, and new research into a cancer target and cholangiocarcinoma treatment.
Johnson & Johnson faces new talc verdicts in Minnesota and Pennsylvania totaling over $10 million, with 67,000+ lawsuits pending. Meanwhile, the FDA approved a new monthly dosing for RYBREVANT FASPRO, and the company launched its Shockwave C2 Aero coronary catheter globally.
A study identified host-response plasma protein candidate biomarkers to predict venous thromboembolism risk after pleural mesothelioma surgery. The exploratory cohort included 18 patients.
Johnson & Johnson settled two cosmetic talc cases in March 2026, one before jury selection in Florida and another after opening statements in Washington, as the company faces multiple trials scheduled for April.
The CheckMate 743 trial reports five-year outcomes for nivolumab plus ipilimumab versus chemotherapy as first-line treatment for unresectable pleural mesothelioma, demonstrating sustained overall survival benefit.
A Philadelphia jury found Johnson & Johnson liable for a woman's ovarian cancer death linked to talc-based baby powder, awarding $250,000 in damages. The verdict marks the first plaintiffs' win in Philadelphia's talc mass tort litigation.
The FDA has approved Novocure's Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment for this patient group in decades. A trial of 571 patients showed a two-month improvement in overall survival when combined with chemotherapy.
Researchers have developed attenuated Listeria bacteria therapies that boost innate immune cells to fight cancer. Two approaches target colorectal cancer and pediatric leukemia, with FDA clearance expected soon for trials in children.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07705334 |
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT07705074 |
FAPI PET Imaging - An Exploratory Study |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07602946 |
SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07563738 |
A 2-part Phase 1/2 Open-label Trial on ODM-212 |
RECRUITING | PHASE1/PHASE2 |
| NCT07514793 |
Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07420010 |
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07277413 |
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07131345 |
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07126509 |
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma |
RECRUITING | NA |
| NCT07072143 |
An International Study on Pediatric Patients With Rare Tumors. |
RECRUITING |
